AUTISM: THE BRAIN ON FIRE
NEUROINFLAMMATION
Friends,
This information is for doctors, life scientists, and interested parents. I included numerous research publications, meta-analyses, and systematic reviews. I hope it will help you better understand autism and support your studies and treatments.
THE VULNERABLE BRAIN
The brain was once believed to be protected behind an impenetrable barrier, immune from infection and immune disturbance. That belief no longer holds. The developing brain is, in fact, deeply vulnerable—not only to systemic inflammation but to direct and indirect effects of infectious agents, many of which begin their influence long before birth.
TORCH INFECTIONS AND CHRONIC PATHOGENS
Among these, the TORCH group of infections—Toxoplasma gondii, Rubella virus, Cytomegalovirus (CMV), Herpes simplex virus (HSV), and others such as Zika virus, Epstein–Barr virus (EBV), and Human herpesvirus-6 (HHV-6)—occupy a central role. These pathogens share a critical characteristic: they can cross the placenta, persist in tissues, and establish latent or chronic infections (Haddad et al., 2023; Yockey & Iwasaki, 2023).
Numerous studies have demonstrated that prenatal or early-life exposure to these pathogens is associated with:
• structural abnormalities of the brain
• altered cortical development
• long-term immune dysregulation
• increased risk of neurodevelopmental disorders
(Estes & McAllister, 2016; Knuesel et al., 2014; Brown & Derkits, 2010; Han et al., 2023; Careaga et al., 2024)
But their most insidious effect is not acute damage—it is the induction of chronic neuroinflammation.
CHRONIC NEUROINFLAMMATION
Once introduced, these pathogens may persist in:• neural tissue• glial cells• endothelial cells of the blood–brain barrier
Even in a latent state, they continue to stimulate the immune system, generating a low-grade, continuous inflammatory signal. This transforms the brain into a site of ongoing immune activation (Clarke et al., 2024; Müller, 2024).
MICROGLIA ACTIVATION
Microglia are first responders to brain infection. In chronic infection, they do not deactivate—they remain chronically activated.
Persistent infections such as:
• CMV and HSV (neurotropic herpesviruses)
• EBV and HHV-6 (immune-modulating viruses)• Toxoplasma gondii (intracellular parasite with brain tropism)
• Mycoplasma pneumoniae and Chlamydia pneumoniae (chronic intracellular bacteria)
have all been shown to:
• directly infect or interact with microglia
• alter microglial gene expression
• induce a prolonged pro-inflammatory phenotype
(Pearce et al., 2018; Chew et al., 2013; Parlog et al., 2015; Bennett & Molofsky, 2023; Paolicelli & Ferretti, 2023)
Instead of returning to a resting, regulatory state, microglia become chronically reactive.
PATHOLOGICAL SHIFT IN MICROGLIA
This leads to a pathological shift:
SENSORY SYSTEM DISRUPTION
TORCH infections and chronic pathogens interfere with sensory systems through several converging mechanisms:
Abnormal Synaptic Pruning
CMV and HSV infections disrupt synaptic development
Microglia remove critical synapses needed for sensory filtering.
Excitatory–Inhibitory Imbalance
Cytokines induced by infection increase glutamatergic activity.
GABAergic inhibition is reduced.
Thalamocortical Dysregulation
The thalamus, essential for sensory gating, is highly sensitive to inflammatory signals.
The result is a brain that cannot properly regulate incoming stimuli (Goines & Ashwood, 2023; Müller, 2024).
Clinically, this appears as:
• hypersensitivity to sound (auditory hyperreactivity)
• tactile defensiveness
• visual overstimulation
• paradoxical sensory-seeking behaviors
These are not behavioral anomalies—they are neurobiological consequences of infection-driven inflammation.
MOTOR SYSTEM DISRUPTION
The motor system is equally vulnerable.
TORCH pathogens—especially CMV, rubella, and toxoplasma—have long been known to affect:
• cerebellar development
• basal ganglia structures
• corticospinal pathways
Even in subclinical or latent infections, chronic inflammation leads to:
White Matter Abnormalities
Inflammation impairs oligodendrocyte function.
Myelination becomes irregular or delayed.
Cerebellar Dysfunction
Purkinje cells are highly sensitive to inflammatory damage.
Basal Ganglia Involvement
Infections alter dopamine metabolism.
(Hakimi et al., 2017; Prandovszky et al., 2011; Fields, 2023; Fatemi et al., 2023)
Clinical manifestations of these disruptions can include delayed motor development, poor coordination, abnormal muscle tone, and stereotyped movements, which may impact daily functioning, mobility, and quality of life.
CYTOKINES AND BRAIN DYSFUNCTION
Infection is the trigger. Cytokines are the mediators.
TORCH infections and chronic pathogens induce a sustained elevation of pro-inflammatory cytokines, particularly:
• IL-6
• TNF-α
• IL-1β
• IFN-γ
These cytokines cross or disrupt the blood–brain barrier and act directly within the CNS (Goines & Ashwood, 2023; Careaga et al., 2024).
KEY MECHANISMS
Direct Neurotoxicity
IL-1β and TNF-α impair synaptic plasticity.
Alteration of Neurotransmitters
Glutamate excitotoxicity increases
GABA signaling decreases
Sustained Microglial Activation
Developmental Interference
Maternal immune activation alters fetal brain development.
(Estes & McAllister, 2016; Meyer et al., 2009; Han et al., 2023)
CYTOKINE EFFECTS ON SENSORY SYSTEMS
Elevated cytokines lead to:
• hyperexcitable sensory cortex
• impaired filtering of stimuli
• disrupted neural oscillations
This produces a sensory profile with hypersensitivity, intolerance to stimuli, and unpredictable responses, which can interfere with daily activities and social interactions.
CYTOKINE EFFECTS ON MOTOR SYSTEMS
Cytokines disrupt motor pathways via:
• dopaminergic dysfunction (basal ganglia)
• cerebellar inflammation
• cortical motor instability
Resulting in:
• dyspraxia
• motor delay
• repetitive behaviors
CHRONIC INFECTION AS A SUSTAINED DRIVER
Unlike acute infections, TORCH pathogens and chronic microbes do not disappear. They persist as latent viral reservoirs (herpesviruses), intracellular niches (Chlamydia, Mycoplasma), or cyst forms (Toxoplasma).
Their persistence leads to:
• continuous immune activation
• episodic reactivation
• cumulative neural damage
This explains:
• fluctuating symptoms
• regression after illness
• partial and temporary responses to therapy
The brain remains in a state of chronic immune stimulation—a fire that never fully extinguishes (Clarke et al., 2024; Müller, 2024).
A UNIFIED PATHOPHYSIOLOGICAL AXIS
When integrated, the process becomes clear:
(Paolicelli & Ferretti, 2023; Careaga et al., 2024)
THE BRAIN UNDER SIEGE
The “Brain on Fire” is not a metaphor—it is a biological reality shaped by infection and immune response.
TORCH pathogens and chronic infections:
• initiate inflammation
• sustain microglial activation
• distort neural development
• disrupt sensory and motor systems
The consequences are profound—but they are not random. They follow a pattern. A mechanism. A chain of events that can be studied, understood, and potentially interrupted.
This shifts the paradigm: From an unknown developmental disorder to infection-driven, immune-mediated brain dysfunction
A MESSAGE TO PHYSICIANS AND LIFE SCIENTISTS
A developing brain exposed to chronic inflammation may change in ways that become harder to reverse over time. Early processes are missed, and later stages are treated as fixed conditions.
And yet, there is hope.
If we recognize the burden of infections as a central mechanism, we gain a path forward. Disease can be approached not as a static state, but as an ongoing biological process—one that may be influenced, reduced, or even partially reversed.
This requires a shift in thinking. From isolated diagnoses to integrated systems.From symptoms to mechanisms.From classification to investigation.
I have seen both extremes of the microbial world, the acute and the hidden. The first terrifies us. The second transforms us.
Many modern diseases may begin long before they are diagnosed—with infections that were never fully cleared, never recognized, or never taken seriously.
This is the burden we carry. And understanding it may be the key to changing how we treat disease in the future.
Dr. Ken Alibek,
MD, PhD, ScD
April 18, 2026